CN116173099A - Application of Ertian oil in preparation of product for treating respiratory tract virus infection - Google Patents
Application of Ertian oil in preparation of product for treating respiratory tract virus infection Download PDFInfo
- Publication number
- CN116173099A CN116173099A CN202310418896.4A CN202310418896A CN116173099A CN 116173099 A CN116173099 A CN 116173099A CN 202310418896 A CN202310418896 A CN 202310418896A CN 116173099 A CN116173099 A CN 116173099A
- Authority
- CN
- China
- Prior art keywords
- oil
- product
- virus
- use according
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002345 respiratory system Anatomy 0.000 title claims abstract description 11
- 230000009385 viral infection Effects 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title description 4
- 241000700605 Viruses Species 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 17
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 11
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 15
- 230000000241 respiratory effect Effects 0.000 claims description 11
- 244000309467 Human Coronavirus Species 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 241000711920 Human orthopneumovirus Species 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 abstract description 16
- 230000005764 inhibitory process Effects 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 7
- 230000000312 effect on influenza Effects 0.000 abstract 1
- 241000007181 unidentified human coronavirus Species 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 47
- 235000019198 oils Nutrition 0.000 description 47
- 210000004027 cell Anatomy 0.000 description 25
- 239000002356 single layer Substances 0.000 description 16
- 231100001274 therapeutic index Toxicity 0.000 description 16
- 241000711467 Human coronavirus 229E Species 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 239000012895 dilution Substances 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000010413 mother solution Substances 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000000120 cytopathologic effect Effects 0.000 description 7
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 6
- 201000009240 nasopharyngitis Diseases 0.000 description 6
- 235000019477 peppermint oil Nutrition 0.000 description 6
- 231100000028 nontoxic concentration Toxicity 0.000 description 5
- 108010019160 Pancreatin Proteins 0.000 description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 229940055695 pancreatin Drugs 0.000 description 4
- 229960000329 ribavirin Drugs 0.000 description 4
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 4
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 229940116229 borneol Drugs 0.000 description 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 201000005264 laryngeal carcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides application of the diAN_SNer oil in preparing a product for treating respiratory tract virus infection, relates to the field of medicines, has obvious inhibition effect on influenza virus FM1 strain and human coronavirus HCOV-229E strain in-vitro culture A549 cytopathy, has inhibition effect on hep-2 cytopathy caused by respiratory tract syncytial virus in-vitro culture, and can be used for preparing the product for treating respiratory tract virus infection.
Description
Technical Field
The invention relates to the field of medicines, in particular to application of diurnal oil in preparing a product for treating respiratory tract virus infection.
Background
The second day oil is a wind-dispelling stimulant, and is commonly used for common cold, dizziness or heatstroke, and its main ingredients are menthol, peppermint oil and borneol.
For the two-day oil, literature: zhou Yanwen, jiang Weizhe, cai Guangming, etc. two-day oil is useful for treating common cold and safety study [ J ]. University of Guangxi Chinese medicine,2003, 6 (002): 1-3. Two-day oil is disclosed for alleviating early symptoms of common cold, such as headache, nasal obstruction, nasal discharge, sneeze, etc., but its use in the preparation of a product for treating respiratory viral infections is not disclosed, and it is pointed out that two-day oil is useful only for the early symptoms of nasopharyngeal catarrh of common cold, but for the late, severe, viral or bacterial-combined common cold, a targeted drug treatment should be used.
However, for key components in the two-day oil, such as peppermint oil, the prior art (e.g., schuhmacher A, reichling J, schnitzler P Virucidal effect of peppermint oil on the enveloped viruses herpes simplex virus type 1 and type 2 in vitro [ J ]. Phytomedicine,2003, 10 (6-7): 504-510.) also discloses that peppermint oil has an inhibitory effect on two subtypes of herpes simplex virus (HSV 21, HSV 22) and has no relevant description of peppermint oil inhibiting new coronaviruses and the like.
At present, other prior art also has no related research on the application of the two-day oil in preparing products for treating respiratory tract virus infection.
Aiming at the problem, the application field of the two-day oil is further expanded, and the research on the application of the two-day oil in preparing products for treating respiratory tract virus infection is necessary.
Disclosure of Invention
Aiming at the problems existing in the prior art, the invention provides the application of the diAN_SNer oil in preparing a product for treating respiratory tract virus infection.
The invention provides application of a two-day oil in preparation of a product for treating respiratory tract virus infection, wherein the concentration of the two-day oil in the product is less than or equal to 0.25mg/mL.
Further, the respiratory viruses include one or more of influenza virus, human coronavirus, and respiratory syncytial virus.
Preferably, the respiratory viruses include one or more of influenza virus FM1 strain, human coronavirus HCOV-229E strain and respiratory syncytial virus.
Further, the respiratory virus is a human coronavirus HCOV-229E strain.
Further, the concentration of the two-day oil in the product is 0.032-0.25mg/mL.
Preferably, the concentration of the two-day oil in the product is 0.0625-0.25mg/mL.
Further preferably, the concentration of the two-day oil in the product is 0.125-0.25mg/mL.
In some specific embodiments, the concentration of the two-day oil in the product is 0.0625-0.25mg/mL when the respiratory virus is influenza virus FM1 strain, 0.032-0.25mg/mL when the respiratory virus is human coronavirus HCOV-229E strain, and 0.125-0.25mg/mL (excluding 0.125 mg/mL) when the respiratory virus is respiratory syncytial virus.
Further, the product comprises a medicament.
Further, the components of the medicine comprise the common oil and pharmaceutically acceptable auxiliary materials.
Further, the dosage forms of the medicine comprise tablets, granules, capsules, dripping pills, gels, pastes and patches.
Further, the components of the two-day oil comprise menthol, peppermint oil and borneol.
The invention has the technical effects that:
the two-day oil has obvious inhibition effect on the in-vitro culture A549 cytopathy of the influenza virus FM1 strain and the human coronavirus HCOV-229E strain, and simultaneously has inhibition effect on the in-vitro culture hep-2 cytopathy caused by respiratory syncytial virus, and the comprehensive therapeutic index indicates that the two-day oil has more obvious antiviral effect.
Detailed Description
Other advantages and effects of the present invention will become apparent to those skilled in the art from the following disclosure, which describes the embodiments of the present invention with reference to specific examples. The invention may be practiced or carried out in other embodiments that depart from the specific details, and the details of the present description may be modified or varied from the spirit and scope of the present invention.
Before the embodiments of the invention are explained in further detail, it is to be understood that the invention is not limited in its scope to the particular embodiments described below; it is also to be understood that the terminology used in the examples of the invention is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the invention.
Where numerical ranges are provided in the examples, it is understood that unless otherwise stated herein, both endpoints of each numerical range and any number between the two endpoints are significant both in the numerical range. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
It should be noted that the raw materials used in the present invention are all common commercial products, and therefore the sources thereof are not particularly limited.
Example 1
1. Test materials
1.1 cell lines: human lung cancer cell A549, human laryngeal carcinoma epithelial cell hep-2 is purchased from Beijing North Innovative biological technology institute, passaged in this room and preserved in liquid nitrogen for later use.
1.2 viral strains: influenza A H1N1 virus (FM 1 strain), human coronavirus 229E (HCOV-229E), respiratory syncytial virus (RSV strain), purchased from the American type standard biological collection (ATCC). The room is passaged and stored in a refrigerator at the temperature of minus 80 ℃ for standby.
1.3 test drug
Is provided by Guangzhou white cloud mountain stars (pharmaceutical industry) stock. Day oil, sample lot number: SE220722a, sample properties: the liquid was clear in a reddish brown color.
Positive control drug: ribavirin granules, manufactured by Sichuan Baili pharmaceutical Co., ltd., batch number 200202. The mother solution of 5mg/mL is prepared by high-purity water before the test, and the mother solution is filtered and sterilized for later use.
1.4 test reagents
TABLE 1 test reagent case
1.5 test instrument
Table 2 test instrument conditions
2. Test method and results
2.1 culturing cells
A549 cells were digested with 0.25% pancreatin according to the conventional method, centrifuged at 1000rpm/min for 5min. Removing pancreatin, adding 10ml DMEM cell culture solution, blowing cells uniformly, inoculating into 96-well cell culture plate at 37deg.C with 5% CO, and 100 ul/well 2 After 24h culture in incubator, cell monolayer was grown for test.
The hep-2 cells were digested with 0.25% pancreatin according to the conventional method, centrifuged at 1000rpm/min for 5min. Removing pancreatin, adding 10ml DMEM cell culture solution, blowing cells uniformly, inoculating into 96-well cell culture plate at 37deg.C with 5% CO, and 100 ul/well 2 After 24h culture in incubator, cell monolayer was grown for test.
2.2 pharmaceutical preparation
Two day oil solution: adding 10 parts of two-day oil and 10 parts of tween-80, uniformly mixing by ultrasonic treatment, adding 180 parts of sterilized water, and dissolving by ultrasonic treatment (without sterilizing again). The cell culture solution 1960 μl and the two-day oil solution 40 μl are uniformly mixed before the test, and the mother solution is the two-day oil mother solution with the concentration of 1mg/ml.
Ribavirin granules: the mother solution of 5mg/mL is prepared by high-purity water before the test, and the mother solution is filtered and sterilized for later use.
The mother liquor concentration is used as the initial concentration in the drug test, and the cell maintenance solution is used for 2-fold dilution in the cytotoxicity test, and the total dilution is 8. The drug effect is tested at TC 0 At 8 dilution concentrations.
2.3 Toxicity test of two-day oil on in vitro culture A549, hep-2 cells
Taking the concentration of the mother solution as the initial concentration, diluting with the cell maintenance solution by 2 times, setting 8 dilutions altogether, adding into the A549 and hep-2 cell culture plates which grow into monolayers, and setting 3 compound wells for each dilution and normal cell control. Placing the culture plate at 37deg.C and 5% CO 2 Culturing in incubator, observing cytopathy condition under daily inverted microscope for 72 hr, and determining minimum dilution multiple (maximum nontoxic concentration TC) of cells without obvious lesion 0 ) And 50% cytotoxicity concentration (TC) was calculated according to Reed-Muench method 50 ）。
Cytopathy is judged according to a grade 6 standard:
-: the cells grow normally without lesions;
and (3) the following steps: cytopathic effect is less than 10% of the whole monolayer;
+: cytopathy accounts for less than about 25% of the whole monolayer;
++: cytopathy accounts for less than about 50% of the whole monolayer;
+++: cytopathy accounts for less than 75% of the whole monolayer;
++++: cytopathy accounts for about 75% or more of the whole monolayer.
TABLE 3 toxic effects of two day oil on in vitro culture A549 cells
Note that: cytopathic scoring: "+" =1, "+++" =2, "++", etc the number of the samples is =2, "+++", etc =4, 3 and scoring the multiple holes respectively.
Table 3 the results show that: maximum non-toxic concentration of the two-day oil (TC) 0 ) The dilution is that the mother solution is diluted by 1:4 times, the drug concentration is 0.25mg/ml, TC 50 The value was 0.335mg/ml.
TABLE 4 toxic effects of two day oil on in vitro culture of hep-2 cells
Note that: cytopathic scoring: "+" =1, "+++" =2, "++", etc the number of the samples is =2, "+++", etc =4, 3 scoring the multiple holes separately
Table 4 the results show that: maximum non-toxic concentration of the two-day oil (TC) 0 ) The dilution is that the mother solution is diluted by 1:4 times, the drug concentration is 0.25mg/ml, TC 50 The value was 0.335mg/ml.
2.4 Inhibition of two-day oil on in vitro culture A549 cytopathy caused by FM1 strain and HCOV-229E strain of influenza virus
Taking A549 cell culture plates growing into monolayers, pouring out the culture solution, and respectively inoculating 100TCID 50 H1N1 influenza virus (FM 1 strain), human coronavirus 229E (HCOV-229E), 100. Mu.l/well, 37℃in 5% CO 2 After adsorbing for 1h in an incubator, removing virus liquid, flushing the cell surface with cell maintenance liquid for 3 times, sequentially adding each liquid medicine with 7-8 dilutions below the maximum non-toxic concentration, 100 μl/hole, and simultaneously setting normal cell control, virus control and ribavirin Lin Duizhao. Placing at 37deg.C 5% CO 2 Culturing in incubator, observing cytopathy condition under inverted microscope every day, after 72h the virus control group cytopathy is the time of the++ to+++ is recorded the test results are recorded. 50% Inhibition Concentration (IC) calculated as Reed-Muench 50 ) And Therapeutic Index (TI), ti=tc 50 /IC 50 。
Cytopathy is judged according to a grade 6 standard:
-: the cells grow normally without lesions;
and (3) the following steps: cytopathic effect is less than 10% of the whole monolayer;
+: cytopathy accounts for less than about 25% of the whole monolayer;
++: cytopathy accounts for less than about 50% of the whole monolayer;
+++: cytopathy accounts for less than 75% of the whole monolayer;
++++: cytopathy accounts for about 75% or more of the whole monolayer.
TABLE 5 inhibition of respiratory viruses by two day oil on in vitro culture of A549 cells
Note that: cytopathic scoring: "+" =1, "+++" =2, "++", etc the number of the samples is =2, "+++", etc =4, 3 scoring the compound holes respectively;
IC50 units: (two days oil: mg/ml).
Table 5 the results show that: the two-day oil convection virus FM1 strain and the human coronavirus HCOV-229E strain have different degrees of inhibition effects on cytopathy, wherein the two-day oil convection virus FM1 strain and the human coronavirus HCOV-229E strain IC 50 0.045 mg/ml and 0.022 mg/ml, respectively, the therapeutic index TI is 7.89 and 16.14, respectively.
2.5 Inhibition of RSV-induced in vitro culture hep-2 cytopathy by two-day oil
Taking hep-2 cell culture plate growing into single layer, pouring out culture solution, respectively inoculating 100TCID 50 100. Mu.l/well of Respiratory Syncytial Virus (RSV), placed at 37℃in 5% CO 2 After adsorbing for 1h in an incubator, removing virus liquid, flushing the cell surface with cell maintenance liquid for 3 times, sequentially adding 7-8 dilutions of each liquid medicine below the maximum non-toxic concentration, 100 μl/hole, and simultaneously setting normal cell control, virus control and ribavirin (RSV positive control medicine) control. Placing at 37deg.C 5% CO 2 Culturing in incubator, observing cytopathy condition under inverted microscope every day, after 72h the virus control group cytopathy is the time of the++ to+++ is recorded the test results are recorded. 50% Inhibition Concentration (IC) calculated as Reed-Muench 50 ) And Therapeutic Index (TI), ti=tc 50 /IC 50 。
Cytopathy is judged according to a grade 6 standard:
-: the cells grow normally without lesions;
and (3) the following steps: cytopathic effect is less than 10% of the whole monolayer;
+: cytopathy accounts for less than about 25% of the whole monolayer;
++: cytopathy accounts for less than about 50% of the whole monolayer;
+++: cytopathy accounts for less than 75% of the whole monolayer;
++++: cytopathy accounts for about 75% or more of the whole monolayer.
TABLE 6 inhibition of respiratory viruses by two day oils on hep-2 cells cultured in vitro
Note that: cytopathic scoring: "+" =1, "+++" =2, "++", etc the number of the samples is =2, "+++", etc =4, 3 scoring the compound holes respectively; IC50 units: (two days oil: mg/ml).
Table 6 the results show that: two-day oil has various degrees of inhibition on Respiratory Syncytial Virus (RSV) cytopathy, wherein the two-day oil has IC (integrated circuit) on RSV 50 Is 0.178 mg/ml and the therapeutic index TI is 2.0.
Comprehensively considering the values of Therapeutic Indexes (TI), the two-day oil has obvious inhibition effect on the cytopathy of the influenza virus FM1 strain and the human coronavirus HCOV-229E strain cultured in vitro A549, and the Therapeutic Indexes (TI) are respectively 7.89 and 16.14; the two-day oil has an inhibitory effect on the in vitro culture of hep-2 cytopathy caused by respiratory syncytial virus, and the Therapeutic Index (TI) is 2.0. The comprehensive result shows that the two-day oil has better antiviral effect.
3. Conclusion(s)
The two-day oil has obvious inhibition effect on the in-vitro culture A549 cytopathy of the influenza virus FM1 strain and the human coronavirus HCOV-229E strain, and simultaneously has inhibition effect on the in-vitro culture hep-2 cytopathy caused by the respiratory syncytial virus, and the comprehensive therapeutic index indicates that the two-day oil has obvious antiviral effect.
Finally, it should be noted that the above description is only for illustrating the technical solution of the present invention, and not for limiting the scope of the present invention, and that the simple modification and equivalent substitution of the technical solution of the present invention can be made by those skilled in the art without departing from the spirit and scope of the technical solution of the present invention.
Claims (10)
1. The application of the diurnal oil in preparing a product for treating respiratory tract virus infection is characterized in that: the concentration of the two-day oil in the product is less than or equal to 0.25mg/mL.
2. The use according to claim 1, characterized in that: the respiratory viruses include one or more of influenza virus, human coronavirus, and respiratory syncytial virus.
3. The use according to claim 1, characterized in that: the respiratory viruses comprise one or more of influenza virus FM1 strain, human coronavirus HCOV-229E strain and respiratory syncytial virus.
4. The use according to claim 1, characterized in that: the respiratory virus is human coronavirus HCOV-229E strain.
5. The use according to claim 1, characterized in that: the concentration of the two-day oil in the product is 0.032-0.25mg/mL.
6. The use according to claim 1, characterized in that: the concentration of the two-day oil in the product is 0.0625-0.25mg/mL.
7. The use according to claim 1, characterized in that: the concentration of the two-day oil in the product is 0.125-0.25mg/mL.
8. The use according to claim 1, characterized in that: the product comprises a medicament.
9. The use according to claim 8, characterized in that: the components of the medicine comprise the common oil and pharmaceutically acceptable auxiliary materials.
10. The use according to claim 8, characterized in that: the dosage forms of the medicine comprise tablets, granules, capsules, dripping pills, gels, pastes and patches.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310418896.4A CN116173099B (en) | 2023-04-19 | 2023-04-19 | Application of Ertian oil in preparation of product for treating respiratory tract virus infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310418896.4A CN116173099B (en) | 2023-04-19 | 2023-04-19 | Application of Ertian oil in preparation of product for treating respiratory tract virus infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116173099A true CN116173099A (en) | 2023-05-30 |
| CN116173099B CN116173099B (en) | 2023-09-08 |
Family
ID=86434744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310418896.4A Active CN116173099B (en) | 2023-04-19 | 2023-04-19 | Application of Ertian oil in preparation of product for treating respiratory tract virus infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116173099B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104161902A (en) * | 2014-08-25 | 2014-11-26 | 漳州片仔癀药业股份有限公司 | Pharmaceutical composition and novel use of preparation of pharmaceutical composition in preparation of anti-influenza drug |
| US20160166624A1 (en) * | 2012-10-19 | 2016-06-16 | Flutrends International, Llc | Anti-viral compositions |
| CN113209203A (en) * | 2021-05-18 | 2021-08-06 | 江西中医药大学 | Antiviral compound essential oil and application thereof |
| CN113975314A (en) * | 2021-10-27 | 2022-01-28 | 广东罗浮山国药股份有限公司 | Application of oil of dahurian rhododendron leaf in preparing medicine for preventing or treating respiratory infectious diseases |
| CN115372535A (en) * | 2022-08-09 | 2022-11-22 | 广州白云山星群(药业)股份有限公司 | Thin-layer chromatography detection method for two-day oil |
-
2023
- 2023-04-19 CN CN202310418896.4A patent/CN116173099B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160166624A1 (en) * | 2012-10-19 | 2016-06-16 | Flutrends International, Llc | Anti-viral compositions |
| CN104161902A (en) * | 2014-08-25 | 2014-11-26 | 漳州片仔癀药业股份有限公司 | Pharmaceutical composition and novel use of preparation of pharmaceutical composition in preparation of anti-influenza drug |
| CN113209203A (en) * | 2021-05-18 | 2021-08-06 | 江西中医药大学 | Antiviral compound essential oil and application thereof |
| CN113975314A (en) * | 2021-10-27 | 2022-01-28 | 广东罗浮山国药股份有限公司 | Application of oil of dahurian rhododendron leaf in preparing medicine for preventing or treating respiratory infectious diseases |
| CN115372535A (en) * | 2022-08-09 | 2022-11-22 | 广州白云山星群(药业)股份有限公司 | Thin-layer chromatography detection method for two-day oil |
Non-Patent Citations (4)
| Title |
|---|
| 周燕文等: "二天油治疗伤风感冒有效性及安全性研究", 广西中医学院学报, vol. 6, no. 02, pages 1 - 3 * |
| 宝芝林大药房: "伤风感冒可以用二天油吗", pages 1 - 2, Retrieved from the Internet <URL:http://yp.360bzl.com/news-137250.html> * |
| 白云山星群夏桑菊: "不止年货，春节返乡探亲，这些东西也建议带上！", pages 1 - 14, Retrieved from the Internet <URL:http://k.sina.com.cn/article_2165713424_81162a100010136no.html> * |
| 陈召亮等: "中药抗流感作用研究进展", 中国兽医学报, vol. 43, no. 4, pages 807 - 812 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116173099B (en) | 2023-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tolo et al. | Anti-viral activity of the extracts of a Kenyan medicinal plant Carissa edulis against herpes simplex virus | |
| WO2021213058A1 (en) | Application of traditional chinese medicine composition in preparation of drugs for treating or preventing infection with coronaviruses | |
| CN101390869B (en) | Use of high-purity forsythin in preparing bacteriostasis, antivirus medicine | |
| CN107737201B (en) | Antiviral application of cloverleaf extract | |
| US20070123566A1 (en) | Isoflavone derivatives of tectoridin, the preparation thereof and the anti-virus medicines containing the same as an effective constituents | |
| CN113440563B (en) | Compound houttuynia cordata spray and preparation method and application thereof | |
| CN116173099B (en) | Application of Ertian oil in preparation of product for treating respiratory tract virus infection | |
| CN113855654A (en) | A composition for preventing and treating coronavirus infection | |
| CN103118686B (en) | The purposes of Banlangen Polysaccharide in the medicine preparing resisiting influenza virus | |
| US20230173006A1 (en) | Application of traditional chinese medicine composition to preparation of medicine for treating or preventing coronavirus infection | |
| Odimegwu et al. | Anti-respiratory syncytial virus activities of leaf extracts of Alchornea cordifolia and Alchornea floribunda | |
| CN104257745A (en) | Selfheal polyose extractive and preparation method, preparation and application thereof | |
| CN115068452B (en) | Application of aloe-emodin in preparing medicine for preventing and treating African swine fever | |
| JP2016523874A (en) | Pharmaceutical composition effective against viruses | |
| CN105326923A (en) | Fermented plaster for treating rhinitis | |
| CN101537129B (en) | Applications of dendrobium nobile lindl alkaloids in medicines prepared for treating ischemic brain damage and product thereof | |
| CN104997769A (en) | Application of mangiferin in the preparation of antiviral drugs | |
| CN106038535B (en) | Application of the aesculetin in the drug of preparation prevention and treatment II type virus infection of dengue fever | |
| CN103933060A (en) | Application of hedysarum polybotys saccharide in preparation of medicaments or health products for preventing or treating osteoporosis | |
| CN113230253A (en) | Antiviral composition and application thereof in preparation of medicine for preventing and/or treating herpes virus | |
| HK40088390B (en) | Application of ertian you in the preparation of products for the treatment of respiratory viral infections | |
| HK40088390A (en) | Application of ertian you in the preparation of products for the treatment of respiratory viral infections | |
| CN106511321A (en) | Anti-inflammatory/antivirus composition and medicine | |
| CN115364129B (en) | Application of herba Pileae Scriptae or its extract, and preparation for clearing heat and relieving inflammation in preparation of anti-coronavirus medicine and preparation method thereof | |
| CN113509461B (en) | Application of a ginkgolide composition in the preparation of a drug for treating or preventing coronavirus infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40088390 Country of ref document: HK |